Company Information
Industry 科学研究和技术服务业
Company Introduction 上海益诺思生物技术股份有限公司(股票代码688710)成立于2010年,是国药集团下属中国医药工业研究总院有限公司的控股子公司。秉承“科学引领、质量唯先、诚信敬业、合作共赢”的核心价值观,以科学为引领,以客户为中心。公司先后通过NMPA的GLP认证、美国FDA的GLP检查、OECDGLP认证,AAALAC认证及美国病理学会的CAP认证等,是一家专业的提供生物医药高质量创新药综合研发服务的(CRO)企业。业务范围覆盖早期成药性评价、非临床药效学研究、非临床药代动力学研究、非临床安全性评价研究、临床生物样本分析、生物标志物与转化研究等领域。 经过多年的发展,益诺思目前已拥有7.4万平方米的现代化设施,千余人的研究团队,主要分布在上海、南通。公司具备行业领先的国际化服务能力,与国际标准接轨,为全球医药企业和科研机构提供全方位的、符合国内及国际申报标准的一站式新药研发服务。截至2026年6月30日,助力全球创新药研发NDA/BLA成功案例40余例,IND注册成功案例890余例,协助140余个项目获批了美国、欧盟、韩国及澳洲等国外监管机构的临床注册申报,获批FDANDA/BLA3例。 益诺思致力于为国内外客户提供一站式服务解决方案,朝着“科技创新的引领者,新药研发的加速器,生命健康的守护人”的企业愿景不断努力前进。
Main Business 提供生物医药非临床研究服务为主的综合研发服务(CRO)。
Legal Representative 常艳
Top Executives
董事长:常艳
董事:高莉,罗华菲,翁少羽,庄伟平,常艳
独立董事:李胜彩,邵蓉,范国钦
Top 5 Shareholder
Shareholder name Nature Holding Date
中国医药工业研究总院有限公司限售股20.62%30/09/2026
上海翱鹏企业管理中心(有限合伙)流通A股11.35%30/09/2026
中国医药投资有限公司限售股9.38%30/09/2026
中国医药集团有限公司限售股4.41%30/09/2026
上海张江生物医药基地开发有限公司流通A股3.31%30/09/2026
Company Secretary 李燕
Solicitors 国浩律师(上海)事务所
Auditors 立信会计师事务所(特殊普通合伙)
Tel No 021-50801259
Fax No 021-50801259
Website www.innostarbio.com
Email bo@innostarbio.com
Company Address
Register: 中国(上海)自由贸易试验区郭守敬路199号106室
Office: 中国(上海)自由贸易试验区郭守敬路199号
Listing Date 03/09/2024
Shares Capital
Shares Capital: 140,979,615
Total A Share: 140,979,615
Listed A Share: 92,456,209
Non-tradable A Share: 48,523,406
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.220
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 16.481
Market Capitalization(RMB) 6.472B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.